BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 20200621)

  • 1. Is Jupiter also a god of primary prevention?
    Accad M; Fred HL
    Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 3. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 5. Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
    Ann Intern Med; 2010 Apr; 152(8):I34. PubMed ID: 20404365
    [No Abstract]   [Full Text] [Related]  

  • 6. [Lipid lowering by rosuvastatin: how do statins differ?].
    Laufs U
    Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
    [No Abstract]   [Full Text] [Related]  

  • 7. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipid lowering for primary prevention.
    Yusuf S; Lonn E; Bosch J
    Lancet; 2009 Apr; 373(9670):1152-5. PubMed ID: 19345816
    [No Abstract]   [Full Text] [Related]  

  • 9. Most would fail to benefit from JUPITER Intervention.
    Plonk WM
    J Am Coll Cardiol; 2009 Aug; 54(8):744; author reply 744-5. PubMed ID: 19679258
    [No Abstract]   [Full Text] [Related]  

  • 10. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
    López A; Wright JM
    Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk in uremic patients: darkness after AURORA.
    Robles NR; Macias JF
    Ren Fail; 2010 Jan; 32(2):269-72. PubMed ID: 20199190
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
    Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosuvastatin in patients with elevated C-reactive protein.
    Mak KH; Chan ES
    N Engl J Med; 2009 Mar; 360(10):1039-40; author reply 1041-2. PubMed ID: 19271274
    [No Abstract]   [Full Text] [Related]  

  • 14. Jupiter to Earth: CRP promotes atherothrombosis.
    Jialal I; Devaraj S
    Metab Syndr Relat Disord; 2009 Feb; 7(1):1-3. PubMed ID: 19183073
    [No Abstract]   [Full Text] [Related]  

  • 15. Public health. U.S. panel favors wider use of preventive drug treatment.
    Couzin-Frankel J
    Science; 2010 Jan; 327(5962):130-1. PubMed ID: 20056859
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Hsia J; MacFadyen JG; Monyak J; Ridker PM
    J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin for cardiovascular prevention: too many uncertainties.
    Prescrire Int; 2009 Aug; 18(102):176. PubMed ID: 19746571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial update II: Jupiter trial, rosuvastatin has greater efficacy in elderly populations.
    Fricker J
    Eur Heart J; 2009 Dec; 30(23):2821. PubMed ID: 19972644
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on the benefits and risks of rosuvastatin therapy.
    Toth PP
    Postgrad Med; 2014 Mar; 126(2):7-17. PubMed ID: 24685964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins in primary prophylaxis of cardiovascular diseases].
    Kobalava ZhD; Villeval'de SV
    Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.